CNR1 and glioma: WIN 55,212-2, a synthetic cannabinoid, is a non-selective CB1/CB2 agonist with demonstrated efficacy in glioma models, reducing proliferation and invasion via reactive oxygen species (ROS) and MAPK/PI3K pathways [20,21].